Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26098881 | 0.83 | TP53 (0.51) | HSD11B1KMOBRD4TP53MDM2 | |
| SCHEMBL16982963 | 0.82 | HSD11B1 (0.45) | HSD11B1BRD4 | |
| SCHEMBL26097001 | 0.80 | TP53 (0.46) | HSD11B1KMOGRM2CYP2C9TP53 | |
| SCHEMBL26097390 | 0.78 | HSD11B1 (0.48) | HSD11B1GRM2 | |
| SCHEMBL19412822 | 0.78 | BRD4 (0.39) | HSD11B1BRD4CASP6 | |
| SCHEMBL17661913 | 0.78 | IRAK4 (0.38) | HSD11B1BRD4 | |
| SCHEMBL26096655 | 0.78 | TP53 (0.44) | HSD11B1KMOGRM2CYP2C9TP53 | |
| SCHEMBL11687575 | 0.77 | IDO1 (0.46) | HSD11B1BRD4 | |
| SCHEMBL2688099 | 0.76 | BRD4 (0.51) | HSD11B1BRD4CASP6KDREPHB4 | |
| SCHEMBL31227202 | 0.76 | KDM4E (0.43) | BRD4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149933-B1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2024-06-12 | — | — | EP | disclosed |
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4149933-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-22 | — | — | EP | disclosed |
| CN-115461337-A | Novel triazolyl derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | HSD11B1 2561/4885KMO 706/4885GRM2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.